Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

“This is quite exciting,” said Dr. Shirish M. Gadgeel, a medical oncologist at the Henry Ford Cancer Institute in Detroit.

This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...